Stanley D. Glick

Albany Medical Center Hospital

2 papers in the library · 117 citations · publishing 2001-2003

Papers

Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.

Pharmacology, biochemistry, and behavior June 1, 2003 Isabelle M. Maisonneuve, Stanley D. Glick 109 citations

18-Methoxycoronaridine (18-MC), a synthetic compound related to iboga, reduces self-administration of multiple addictive drugs in animal models. It decreased intravenous morphine, cocaine, methamphetamine, and nicotine self-administration, as well as oral alcohol and nicotine intake, and eased opioid withdrawal signs, without affecting responding for a nondrug reinforcer (water) or causing apparent toxicity. 18-MC also blocked sensitized dopamine responses to morphine and cocaine in the nucleus accumbens. Receptor studies identified it as a potent antagonist at alpha3beta4 nicotinic receptors. Low-dose combinations of 18-MC with other alpha3beta4 antagonists reduced drug self-administration at otherwise ineffective doses. The findings suggest that alpha3beta4 nicotinic receptor antagonists may offer a novel, broad-spectrum treatment for addiction.

DOI: 10.1016/s0091-3057(03)00119-9 Full text

Chemical Synthesis and Biological Evaluation of 18-Methoxycoronaridine (18-MC) as a Potential Anti-addictive Agent

Current Medicinal Chemistry - Central Nervous System Agents August 1, 2001 Upul K. Bandarage, Martin E. Kuehne, Stanley D. Glick 8 citations

Ibogaine, a psychoactive alkaloid from the West African shrub Tabernanthe iboga, can reduce addictive behavior for up to six months after a single oral dose or three years after four treatments in rats, decreasing self-administration of morphine, cocaine, ethanol, and nicotine. However, ibogaine causes serious side effects including tremors, degeneration of Purkinje cells, and acute depression of water-seeking behavior. To overcome these problems, researchers synthesized 18-methoxycoronaridine (18-MC), a novel iboga alkaloid congener, via a 13-step process with 7% yield. In rats, 18-MC similarly reduces self-administration of these drugs but lacks ibogaine's side effects, suggesting potential as a safer treatment for multiple forms of drug abuse.

DOI: 10.2174/1568015013358608 Addiction Pharmacology Nicotine Indole alkaloid +5